- Medicines and Healthcare products Regulatory Agency
- Part of:
- Patient safety and Clinical trials and investigations
- 26 June 2014
Deficiencies in Omega’s pharmacovigilance system are not thought to affect the safety of the products that they market.
PDF, 598KB, 5 pages
This file may not be suitable for users of assistive technology. Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email email@example.com. Please tell us what format you need. It will help us if you say what assistive technology you use.
Patients using or taking products marketed by Omega Pharma Limited should continue to take their medication, following the instructions in the patient information leaflet. Anyone who is concerned about a medicine that they are taking should contact their pharmacist or doctor for advice.
Omega Pharma Limited has submitted responses to the infringement notice and inspection findings and the proposed corrective and preventative actions have been reviewed during the MHRA re-inspection of Omega Pharma Limited.
Published: 26 June 2014